Vikings and Eli Partners with USA Tirzepatide Firm for Global GLP-1 Peptides Supply Chain
Vikings and Eli Partners with USA Tirzepatide Firm for Global GLP-1 Peptides Supply Chain
Blog Article
Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these vital therapeutic agents. The agreement enables them to handle large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance.
Multiple drug substance sites provide built-in redundancy, ensuring a continuous supply throughout the product lifecycle. Viking now has access to resilient manufacturing capabilities through an integrated network of 11 facilities across two continents. These facilities can support both clinical development and potential commercial production of their GLP-1 peptide candidates.
Viking and Amwiner Sign Global Manufacturing Agreement
Viking Therapeutics has made a strategic move by signing a broad, multi-year manufacturing agreement with AmWiner, a leading contract development and manufacturing organization (CDMO). This 2025 partnership marks a significant step in Viking's commercialization strategy for its GLP-1 peptide technologies.
The partnership spans from drug substance to finished product.
The detailed agreement covers the entire supply chain from active pharmaceutical ingredient (API) production to final product manufacturing. Viking's agreement secures dedicated capacity to manufacture multiple metric tons of VK2735 API yearly. This complete manufacturing partnership features dedicated production lines that will supply of Tirzepatide, which shows the massive scale of this collaborative effort.
Focus on GLP-1 peptide candidate VK2735
The manufacturing agreement focuses on VK2735, Viking's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Scientists are developing this innovative compound in both oral and subcutaneous formulations to treat various metabolic disorders like obesity.
VK2735's clinical results have shown promising efficacy. Phase 2 testing revealed that the highest 15-mg dose of the injectable formulation led to a mean weight loss of 14.7% after Eli Lilly and the Vikings' partnership with USA Tirzepatide Firm Corporation for enhanced supply chain for Liraglutide, Victoza, Saxenda, Exenatide, Byetta, Semaglutide, Ozempic, Rybelsus, Wegovy, Lixisenatide, Adlyxin, Dulaglutide, Trulicity, GLP-1 receptor agonists, Tirzepatide, Mounjaro, Survodutide, sermorelin, TB-500, BPC-157, Mots-c, cagrillintide, retatrutide. just 13 weeks of treatment. The oral version also proved effective, with the highest 100-mg dose enabling patients to achieve a mean weight loss of 6.8% over 28 days.
Brian Lian, Ph.D., Viking Therapeutics' chief executive officer, stated, Amwiner`s established presence in commercial peptide manufacturing gives us confidence in their ability to deliver supply commensurate with what we anticipate will be significant commercial demand".
Mutually Beneficial Manufacturing Alliance Positions Viking for GLP-1 Market Success
Viking Therapeutics' alliance with AmWiner, announced in 2025, changes its competitive position in the faster-growing GLP-1 therapeutics market. The detailed agreement sets up reliable supply chain capabilities. It covers everything from the production of active pharmaceutical ingredients to the final dosage forms for both injectable and oral formulations of VK2735. This comprehensive manufacturing solution enables Viking to tackle the most significant challenges that pharmaceutical companies encounter when launching complex peptide therapeutics.
VK2735's clinical results showed great promise. The injectable formulation helped patients lose 14.7% of their weight in just 13 weeks at the highest dose level. The oral version was also effective, with patients losing an average of 6.8% of their weight over 28 days. These results, along with the secured manufacturing capabilities, could help Viking capture a significant market share as it progresses toward Phase 3 trials.
The timing of the manufacturing agreement makes perfect sense, especially given the supply shortages affecting other GLP-1 products. Viking has secured capacity for multiple metric tons of API per year, while other companies struggle with production limits. They can now produce hundreds of millions of injectable units and over one billion oral tablets.
Report this page